Files
Document type
ArticleVersion
Published versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/208080
Development of a Carvedilol oral liquid formulation for paediatric use
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
Carvedilol (CARV) is an 'off-label' β-blocker drug to treat cardiovascular diseases in children. Since CARV is nearly insoluble in water, only CARV solid forms are commercialized. Usually, CARV tablets are manipulated to prepare an extemporaneous liquid formulation for children in hospitals. We studied CARV to improve its aqueous solubility and develop an oral solution. In this study, we assessed the solubility and preliminary stability of CARV in different pH media. Using malic acid as a solubility enhancer had satisfactory results. We studied the chemical, physical, and microbiological stability of 1 mg/mL CARV-malic acid solution. A design of experiment (DoE) was used to optimize the CARV solution's preparation parameters. A 1 mg/mL CARV solution containing malic acid was stable for up to 12 months at 25 °C and 30 °C and 6 months at 40 °C. An equation associating malic acid with CARV concentrations was obtained using DoE. Microbiological data showed that the use of methylparaben was not necessary for this period of time. We successfully developed an aqueous CARV solution suitable for paediatrics and proven to be stable over a 12-month period.
Subject
Subject (English)
Citation
Citation
CHICLANA RODRÍGUEZ, Blanca, et al. Development of a Carvedilol oral liquid formulation for paediatric use. Pharmaceutics. 2023. Vol. 15, num. 9, pags. 2283. ISSN 1999-4923. [consulted: 11 of August of 2026]. Available at: https://hdl.handle.net/2445/208080